NewAmsterdam Pharma N.V.
NAMS | NASDAQ
$23.09
+$0.51 (+2.26%)
Sep 22, 2026, 11:54 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 22.5M | 45.56M | 14.09M | 102.69M | n/a | n/a |
Cost of Revenue | 59K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 22.44M | 45.56M | 14.09M | 102.69M | n/a | n/a |
Operating Income | -225.68M | -176.29M | -182.97M | -3.56M | -34.98M | -6.63M |
Interest Income | 27.59M | 16.88M | 10.22M | n/a | n/a | 851 |
Pretax Income | -203.82M | -241.6M | -176.91M | -22.63M | -41.79M | -7.02M |
Net Income | -203.82M | -241.6M | -176.94M | -22.63M | -41.79M | -7.02M |
Selling & General & Admin | 106.3M | 70.45M | 37.63M | 19.51M | 5.68M | 1.69M |
Research & Development | 141.83M | 151.41M | 159.42M | 86.74M | 28.97M | 4.94M |
Other Expenses | n/a | n/a | n/a | n/a | 326K | n/a |
Operating Expenses | 248.13M | 221.85M | 197.06M | 106.25M | 34.98M | 6.63M |
Interest Expense | n/a | n/a | 6.8M | 287K | 411K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | 977K | 13.44K |
Cost & Expenses | 248.19M | 221.85M | 197.06M | 106.25M | 34.98M | 6.63M |
Income Tax Expense | n/a | -1K | 27K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 114.4M | 94.36M | 82.16M | 18.97M | 17.75M | 17.75M |
Shares Outstanding (Diluted) | 114.4M | 94.36M | 82.16M | 18.97M | 17.75M | 17.75M |
EPS (Basic) | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 |
EPS (Diluted) | -1.75 | -2.56 | -2.15 | -1.19 | -3.34 | -1.15 |
EBITDA | -242.33M | -241.49M | -176.86M | -22.34M | -41.37M | -6.63M |
EBIT | -242.55M | -241.6M | -176.91M | -22.35M | -41.37M | -6.63M |
Depreciation & Amortization | 220K | 113K | 49K | 9K | 5K | 1.22K |
Add to Watchlist
Select watchlists to add or remove NAMS